Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
An open-label study of ocrelizumab in RRMS patients with suboptimal response to prior DMT
2015-005597-38Phase 3Unknown
- Sponsor
- Roche
- Start
- Mar 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ocrelizumab in multiple sclerosis (MS), sponsored by Roche. Primary endpoint: No Evidence of Disease Activity (NEDA) over 96 weeks. Status: unknown.
02
Drugs
ocrelizumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2015-005597-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005597-38.